Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Debt (2016 - 2019)

Fate Therapeutics (FATE) has disclosed Total Debt for 8 consecutive years, with $13.9 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Total Debt fell 6.28% year-over-year to $13.9 million, compared with a TTM value of $13.9 million through Sep 2019, down 6.28%, and an annual FY2018 reading of $14.9 million, up 0.51% over the prior year.
  • Total Debt was $13.9 million for Q3 2019 at Fate Therapeutics, down from $14.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $19.7 million in Q2 2015 and bottomed at $6.7 million in Q2 2017.
  • Average Total Debt over 5 years is $14.7 million, with a median of $14.8 million recorded in 2018.
  • The sharpest move saw Total Debt soared 2540.08% in 2015, then crashed 54.41% in 2017.
  • Year by year, Total Debt stood at $18.4 million in 2015, then tumbled by 41.84% to $10.7 million in 2016, then soared by 38.55% to $14.8 million in 2017, then increased by 0.51% to $14.9 million in 2018, then decreased by 6.4% to $13.9 million in 2019.
  • Business Quant data shows Total Debt for FATE at $13.9 million in Q3 2019, $14.9 million in Q2 2019, and $14.9 million in Q1 2019.